These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 7614775)

  • 1. Zalcitabine. Clinical pharmacokinetics and efficacy.
    Devineni D; Gallo JM
    Clin Pharmacokinet; 1995 May; 28(5):351-60. PubMed ID: 7614775
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Zalcitabine.
    Shelton MJ; O'Donnell AM; Morse GD
    Ann Pharmacother; 1993 Apr; 27(4):480-9. PubMed ID: 8097417
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Zalcitabine. An update of its pharmacodynamic and pharmacokinetic properties and clinical efficacy in the management of HIV infection.
    Adkins JC; Peters DH; Faulds D
    Drugs; 1997 Jun; 53(6):1054-80. PubMed ID: 9179531
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Studies of zidovudine in combination with didanosine and zalcitabine.
    Jablonowski H
    J Acquir Immune Defic Syndr Hum Retrovirol; 1995; 10 Suppl 1():S52-6. PubMed ID: 8595509
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine. AIDS Clinical Trials Group.
    Collier AC; Coombs RW; Schoenfeld DA; Bassett RL; Timpone J; Baruch A; Jones M; Facey K; Whitacre C; McAuliffe VJ; Friedman HM; Merigan TC; Reichman RC; Hooper C; Corey L
    N Engl J Med; 1996 Apr; 334(16):1011-7. PubMed ID: 8598838
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Zidovudine and lamivudine: results of phase III studies.
    Staszewski S
    J Acquir Immune Defic Syndr Hum Retrovirol; 1995; 10 Suppl 1():S57. PubMed ID: 8595510
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Finding a role for zalcitabine in the HAART era.
    Moyle GJ; Gazzard BG
    Antivir Ther; 1998; 3(3):125-37. PubMed ID: 10682130
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A multicentre study to determine the efficacy and tolerability of a combination of nelfinavir (VIRACEPT), zalcitabine (HIVID) and zidovudine in the treatment of HIV infected Nigerian patients.
    Idoko JA; Akinsete L; Abalaka AD; Keshinro LB; Dutse L; Onyenekwe B; Lhekwaba A; Njoku OS; Kehinde MO; Wambebe CO
    West Afr J Med; 2002; 21(2):83-6. PubMed ID: 12403023
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quality of life outcomes of saquinavir, zalcitabine and combination saquinavir plus zalcitabine therapy for adults with advanced HIV infection with CD4 counts between 50 and 300 cells/mm3.
    Revicki DA; Swartz C; Wu AW; Haubrich R; Collier AC
    Antivir Ther; 1999; 4(1):35-44. PubMed ID: 10682127
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HIV therapy advances. Pediatric antiretroviral choices.
    Spector SA
    AIDS; 1994 Sep; 8 Suppl 3():S15-8. PubMed ID: 7840911
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Zalcitabine. A review of its pharmacology and clinical potential in acquired immunodeficiency syndrome (AIDS).
    Whittington R; Brogden RN
    Drugs; 1992 Oct; 44(4):656-83. PubMed ID: 1281077
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intermittent selection pressure with zidovudine plus zalcitabine treatment reduces the emergence in vivo of zidovudine resistance HIV mutations.
    Izopet J; Sailler L; Sandres K; Pasquier C; Bonnet E; Aquilina C; Puel J; Massip P; Marchou B
    J Med Virol; 1999 Feb; 57(2):163-8. PubMed ID: 9892402
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and efficacy of lamivudine-zidovudine combination therapy in zidovudine-experienced patients. A randomized controlled comparison with zidovudine monotherapy. Lamivudine European HIV Working Group.
    Staszewski S; Loveday C; Picazo JJ; Dellarnonica P; Skinhøj P; Johnson MA; Danner SA; Harrigan PR; Hill AM; Verity L; McDade H
    JAMA; 1996 Jul; 276(2):111-7. PubMed ID: 8656502
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Potent new AIDS drugs underscore promise of combination therapy.
    AIDS Alert; 1996 Jan; 11(1):1-4. PubMed ID: 11363225
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and efficacy of lamivudine-zidovudine combination therapy in antiretroviral-naive patients. A randomized controlled comparison with zidovudine monotherapy. Lamivudine European HIV Working Group.
    Katlama C; Ingrand D; Loveday C; Clumeck N; Mallolas J; Staszewski S; Johnson M; Hill AM; Pearce G; McDade H
    JAMA; 1996 Jul; 276(2):118-25. PubMed ID: 8656503
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of lamivudine in HIV-infected persons with prior exposure to zidovudine/didanosine or zidovudine/zalcitabine.
    Albrecht MA; Hughes MD; Liou SH; Katzenstein DA; Murphy R; Balfour HH; Para MF; Valdez H; Hammer SM;
    AIDS Res Hum Retroviruses; 2000 Sep; 16(14):1337-44. PubMed ID: 11018853
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 3TC/AZT: just another combination.
    GMHC Treat Issues; 1995 Dec; 9(12):2. PubMed ID: 11362997
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of food on pharmacokinetics of zalcitabine in HIV-positive patients.
    Nazareno LA; Holazo AA; Limjuco R; Passe S; Twardy SK; Min B; Massarella JW
    Pharm Res; 1995 Oct; 12(10):1462-5. PubMed ID: 8584481
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Peripheral neuropathy: zalcitabine reassessed.
    Carey P
    Int J STD AIDS; 2000 Jul; 11(7):417-23. PubMed ID: 10919481
    [TBL] [Abstract][Full Text] [Related]  

  • 20. AZT studies reinforce benefits of combination.
    AIDS Alert; 1995 Jan; 10(1):11-2. PubMed ID: 11362167
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.